Alnylam Pharmaceuticals (ALNY) 56.11 $ALNY
Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Aug 07, 3:00PM CDT
--- Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation -
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
Business Wire - Thu Aug 07, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and other Rare Bleeding Disorders (RBD).
Alnylam Pharmaceuticals Down 13.8% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 04, 9:50AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.81% as of today's recent price of $53.76.
Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close.
Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series
Business Wire - Tue Jul 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online "RNAi Roundtables" that it is hosting during July and August. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Downtrend Call Working As Alnylam Pharmaceuticals Stock Falls 13.2% (ALNY)
Comtex SmarTrend(R) - Mon Jul 28, 9:21AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.21% as of today's recent price of $54.13.
Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Business Wire - Tue Jul 22, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The '478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed application includes claims that broadly cover single-stranded or double-stranded, chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target. The allowance of this patent application represents a major advance in Alnylam's intellectual property (IP) estate, since GalNAc-siRNA conjugates enable potent and durable silencing of liver-expressed disease genes with subcutaneous dose administration and a wide therapeutic index. Importantly, this delivery approach is a key component of the company's execution on its "Alnylam 5x15" and broader genetic medicine product strategy.
Shares of ALNY Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 16, 9:14AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 3 weeks, Alnylam Pharmaceuticals has returned 14.81% as of today's recent price of $53.13.
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron and Alnylam Pharmaceuticals . It's a smart play for income investors (3.5% dividend yield)...
Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.
Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.
Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Alnylam Pharmaceuticals Up 17.8% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Tue Jun 24, 11:04AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 1 month, Alnylam Pharmaceuticals has returned 17.78% as of today's recent price of $68.53.
Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Aug 07, 3:00PM CDT
--- Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation -
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
Business Wire - Thu Aug 07, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and other Rare Bleeding Disorders (RBD).
Alnylam Pharmaceuticals Down 13.8% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 04, 9:50AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.81% as of today's recent price of $53.76.
Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close.
Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series
Business Wire - Tue Jul 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online "RNAi Roundtables" that it is hosting during July and August. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Downtrend Call Working As Alnylam Pharmaceuticals Stock Falls 13.2% (ALNY)
Comtex SmarTrend(R) - Mon Jul 28, 9:21AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.21% as of today's recent price of $54.13.
Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Business Wire - Tue Jul 22, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The '478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed application includes claims that broadly cover single-stranded or double-stranded, chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target. The allowance of this patent application represents a major advance in Alnylam's intellectual property (IP) estate, since GalNAc-siRNA conjugates enable potent and durable silencing of liver-expressed disease genes with subcutaneous dose administration and a wide therapeutic index. Importantly, this delivery approach is a key component of the company's execution on its "Alnylam 5x15" and broader genetic medicine product strategy.
Shares of ALNY Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 16, 9:14AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 3 weeks, Alnylam Pharmaceuticals has returned 14.81% as of today's recent price of $53.13.
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron and Alnylam Pharmaceuticals . It's a smart play for income investors (3.5% dividend yield)...
Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.
Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.
Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.
Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Alnylam Pharmaceuticals Up 17.8% Since SmarTrend Uptrend Call (ALNY)
Comtex SmarTrend(R) - Tue Jun 24, 11:04AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 1 month, Alnylam Pharmaceuticals has returned 17.78% as of today's recent price of $68.53.
